Does multiple myeloma come back more aggressively each time? What does it mean to have MGUS? How do you know if myeloma is high risk, and what side effects can dexamethasone cause? In this Q&A, Joseph Mikhael and Beth Faiman PhD answer patient and care partner questions.

#mmsm

CHMP Recommends SC Isatuximab Via On-Body Injector for Multiple Myeloma | OncLive The EMA’s CHMP has recommended the approval of subcutaneous isatuximab via on-body injector for the treatment of multiple myeloma.

The EMA’s CHMP has recommended the approval of subcutaneous isatuximab via on-body injector for the treatment of multiple myeloma. #mmsm #hematology #oncology
www.onclive.com/view/chmp-re...

EMA Approves Daratumumab Administration by Patients/Caregivers for Multiple Myeloma | OncLive Subcutaneous daratumumab was approved in Europe for patient or caregiver administration in multiple myeloma.

💥 Self-administrated subcutaneous daratumomab has been approved by the EMA, providing patients with improved QOL and treatment flexibility.

Full details 🇪🇺: www.onclive.com/view/ema-app...

#mmsm #oncology

Starting soon! ⏰ Don't miss IMF Scientific Advisory Board member Dr. Sagar Lonial LIVE answering your questions in an exclusive #MyelomaActionMonth Q&A! Join us ➡️ https://www.facebook.com/events/922951070141613/

#MoreThanMyeloma #mmsm

Today! 📌🗓️ Don't miss IMF Scientific Advisory Board member Dr. Sagar Lonial LIVE answering your questions in an exclusive March 25th Myeloma Action Month Q&A! RSVP now by clicking “Going” here: https://www.facebook.com/events/922951070141613/

#MoreThanMyeloma #MyelomaActionMonth #mmsm

Researchers propose the removal of an sFLC ratio ≥100 as a standalone myeloma-defining event in the IMWG diagnostic criteria for #MMsm, as new findings indicate the previously cited 80% risk of disease progression at two years may be substantially lower: https://ow.ly/JCfw50YwhmM
#HemeSky #OncSky

MRD-Based End Point Set to Surge Under FDA Guidance in Multiple Myeloma | OncLive Multiple experts weigh in on the potential of MRD as a primary end point following recently issued FDA draft guidance for the end point in myeloma.

WATCH 👀: Experts from @fredhutch.org, @mskcancercenter.bsky.social, and @nyulangonepccsm.bsky.social discuss recent @fda.gov draft guidance for the use of MRD as an endpoint for accelerated approvals in multiple myeloma.

See the whole video here ➡️: www.onclive.com/view/mrd-bas...

#mmsm #oncology

Original post on mastodon.social

Aviation weather for Santa Lucia Air Force Base airport in Mexico area (Mexico) is “MMSM 191749Z 36012KT 9SM SKC 20/M03 A3038 RMK SLP133 57007 900 HZY” : See what it means on https://www.bigorre.org/aero/meteo/mmsm/en #santaluciaairforcebaseairport #airport #mexico #mmsm #nlu #metar #aviation […]

Join Drs. Brea Lipe and Sagar Lonial on HemeTalks as they explore high-risk smoldering multiple myeloma through a patient case, covering diagnosis, risk, management, and early intervention trial insights. Listen now: https://ow.ly/C2K150Ywslp

#Hematology #MMsm #HemeSky #MedSky

Compared with #pomalidomide and #dexamethasone, #venetoclax and dexamethasone did not produce statistically different PFS in those with R/R t(11;14) multiple #myeloma #MMsm, an indication that the combo may not be a good option in this patient population: https://ow.ly/Z0Pf50YsTST
#HemeSky #MedSky

IMF Scientific Advisory Board member Dr. Sagar Lonial is going LIVE to answer your questions in this exclusive March 25th Myeloma Action Month Q&A! RSVP now by clicking “Going” here: https://www.facebook.com/events/922951070141613/

#MoreThanMyeloma #MyelomaActionMonth #mmsm

According to results from a recent phase II study, most patients with drug-resistant, true #extramedullary #myeloma responded to dual treatment with #talquetamab plus #teclistamab, with researchers observing a 61% PFS and 74% OS at 12 months: https://ow.ly/q6gI50YpblV #MMsm
#HemeSky #MedSky

IMF Chief Medical Officer Dr. Joseph Mikhael and Dr. Melissa Alsina from Moffitt Cancer Center are going LIVE on March 14 in honor of Myeloma Action Month. RSVP for the free Q&A now at https://www.facebook.com/events/1579804813252696

#MoreThanMyeloma #MyelomaActionMonth #mmsm

#KansasCity: Connect with the myeloma community, build your support network, ask the experts your questions, find support in your community, and for FREE on March 28, 2026! Will we see you there? Save your seat before spots are gone: https://mmsm.link/3Ns8Dox

#mmsm

FDA approves teclistamab plus daratumumab hyaluronidase-fihj (Tec-Dara) for relapsed or refractory multiple myeloma patients who have received at least one prior line of therapy. Learn more: https://mmsm.link/fda-approves-tec-dara
#mmsm

🚨BREAKING🚨: The @fda.gov has approved teclistamab plus subcutaneous daratumumab for relapsed/refractory multiple myeloma after at least 1 prior line of therapy. #mmsm #hematology
www.onclive.com/view/fda-app...

Bring your family, friends, & furry companions for a fun-filled day of community! Together we’ll walk, play, & raise funds for life-changing myeloma research. Register at www.classy.org/event/2026-los-angeles-m... #IMFMiraclesforMyeloma #mmsm #losangeles

Let's make a difference together! Join us in sunny #LosAngeles on March 21 to get moving for a day of family fun, or support online from your home. Register now at www.classy.org/event/2026-los-angeles-m...

#IMFMiraclesforMyeloma #MoreThanMyeloma #mmsm

#Detroit community! If you're affected by #myeloma, join us at our FREE Myeloma Community Workshop on June 27! Learn about myeloma treatment options, get your questions answered by the experts, and so much more. Sign up now before spots are gone: https://mmsm.link/4qz1zVQ

#mmsm

#KansasCity myeloma community, will we see you at our IMF Myeloma Community Workshop on March 28? Join us for expert advice, myeloma education, Q&A sessions with the experts, and more! Save your seat before spots are gone: https://mmsm.link/3Ns8Dox

#mmsm #Missouri

Myeloma community, get your questions ready! Join myeloma expert and IMF Dr. Scientific Advisory Board member Dr. Sagar Lonial for a free live Q&A on March 25. RSVP for the free event at https://www.facebook.com/events/922951070141613/

#MoreThanMyeloma #MyelomaActionMonth #mmsm

Original post on mastodon.social

Aviation weather for Santa Lucia Air Force Base airport in Mexico area (Mexico) is “SPECI MMSM 231742Z 31004KT 8SM SKC 13/01 A3049 RMK HZY” : See what it means on https://www.bigorre.org/aero/meteo/mmsm/en #santaluciaairforcebaseairport #airport #mexico #mmsm #nlu #metar #aviation […]

FDA Grants Priority Review to Iberdomide for Multiple Myeloma - Oncology Nurse Advisor The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.

@fda.gov grants Priority Review to iberdomide for #RRMM.

• Target: E3 ligase modulator (CELMoD)
• Phase 3 EXCALIBUR results: Improved PFS
• Target action date: May 2026

Insights via @medicalprofref.bsky.social.

Read the review: https://bit.ly/3Olgg0s

#mmsm #MultipleMyeloma #FDA

Myeloma community, we want to see you at our Living Well With Myeloma webinar! Join us online on Tuesday, March 10 to learn about movement for myeloma patients and care partners. Register now at https://mmsm.link/46ZdRPl

#mmsm
#MoreThanMyeloma

March Myeloma Action Month will be here soon! We Are #MoreThanMyeloma. Get your merch today to be prepared for March! Raise awareness, shop now at https://international-myeloma-foundation.myshopify.com/

#MyelomaActionMonth #bloodcancer #mmsm

Fanart of Malcolm's Midnight Snack Mysteries!

#bhm #mmsm #indieanimation @leisl.bsky.social

FDA Guidance Signals Shift Toward MRD-Driven Accelerated Approvals in Multiple Myeloma | OncLive Experts break down the FDA’s draft guidance on the use of MRD end points to support accelerated drug approvals in multiple myeloma.

Following the FDA's draft guidance on MRD end points to support accelerated approvals in multiple myeloma, OncLive spoke with experts to gather their insights what this guidance means for future clinical trials #mmsm #oncology

Sign up and read more: www.onclive.com/view/fda-gui...

In this recent Blood Cancer Discovery article, the authors identified the inhibitor of DNA binding (ID) genes as putative suppressors of multiple #myeloma cell fitness.

▶️ Check it out: Dysregulation of the ID2–TCF3 Axis Supports #MultipleMyeloma Cell Growth buff.ly/ku1k1kl #MMSM

WATCH: Kenneth Jin Chang Lim, MBBS, discusses a study investigating the use of dexamethasone prophylaxis to reduce rates of neurotoxicity in myeloma with high ALC after CAR T-cell therapy. @astct.bsky.social @cibmtr.bsky.social #Tandem26 #hematology #mmsm
www.onclive.com/view/dr-lim-...

What do you bring with you to every conference❓

Check out how experts at #Tandem26 answered. 😂

@astct.bsky.social @cibmtr.bsky.social #mmsm #lymsm #leusm #oncology
#hematology

Watch the whole video here ➡️: www.onclive.com/shorts/hemat...